Home

GlycoImaging

GlycoImaging is a European Training Network (ETN) funded by the European Commission under the Horizon 2020 Marie Skłodowska-Curie Action, with the aim of developing the next generation tools for cancer research and diagnostics. 5 research groups, spread across 5 universities and institutes and 3 industrial partners in 4 different countries have come together to train a new generation of chemists/biologists through an EU-wide PhD training network

Learn more about GlycoImaging 

Are you in the beginning of your research career?

GlycoImaging offers 8 positions in Europe. See all available positions here.

8 PhD student positions are open

Who can apply?

To qualify as an ESR you must:

  • be in the first four years of your research career, since, for example, completion of your Master’s degree,
  • have the background and expertise required for the position,
  • not already possess a doctorate degree,
  • be willing to move to a country within the network  in which you have not lived for more than 12 months over the last 3 years,
  • be proficient in both written and spoken English.

Application

Positions

ESR1 Malmö University
ESR2 Umeå University
ESR3 Turku University
ESR4 BAM
ESR5 BAM 
ESR6 PHIAB
ESR7 Copenhagen University
ESR8 Copenhagen University

This is GlycoImaging

A major challenge in the war against cancer is to find ways to diagnose and treat the disease at an early stage. Cancer occurs through a multistage process where cells are transformed to malignant tumors. Of essence is to discover the tumor at an early stage where the cancer is still curable. This calls for sensitive and effective diagnostic tools that can sense the cellular state early in the process. In GlycoImaging we will address this need while exploiting novel synthetic probes targeting tumor specific glycans. These “plastic antibodies” will be developed and used for real-time visualization of cellular cancer biomarkers and in low-cost clinical diagnostics.

Aims of the Glycoimaging project

GlycoImaging will aim to develop and implement highly promising glycan specific probes in clinically relevant cancer diagnostics technologies. We will develop glycan-specific nanoprobes alongside digital holography for real-time visualization of cancer biomarkers and use in low-cost clinical diagnostics, glycan-specific cell separations and in life science and education.

Partners in Glycoimaging

By matching polymer/materials research groups with leading molecular biologists and diagnostics institutes together with SMEs and a leading diagnostic company we have created a highly interdisciplinary research-training network with ambitious scientific goals and an attractive training program.

The GlycoImaging-specific objectives will be reached by all partners through a structured four year work plan comprising five work packages while exploiting the synergy between the leading groups in the field of cancer, glycan targeting, molecular imprinting, and by using in vivo model animal systems

Development of molecularly imprinted polymers for glycan specific detection

In GlycoImaging we will show that very specific and defined reagents, in the form of molecularly imprinted polymers (MIPs) or “plastic antibodies” combined with innovative imaging technologies can fill an unmet need in oncology. Being of nonbiological origin, engineered MIPs are extremely robust, resist denaturing solvents and high temperatures and can be reproducibly produced at low cost.  Being devoid of the limitations of antibodies and lectins MIPs can potentially overcome many of the problems in the current detection strategies. Recent reports on “plastic antibodies” mimicking antibodies with respect to both size and antigen binding in vitro and in vivo were met with particular excitement. Independent reports have shown that the technology may now offer the much needed breakthrough in the field of glycan specific detection. This warrants the further development of such receptors,  which could be used for e.g. cell imaging, cell sorting, cellular glycosylation analysis or for the selective inhibition of cell surface interactions.